Atara Biotherapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered board introductions, four key proposals, and voting procedures. All proposals—including director elections, executive compensation, equity plan amendment, and auditor ratification—were approved, with final results to be filed in a Form 8-K.
Fiscal Year 2025
-
The meeting covered director elections, executive compensation, auditor ratification, and voting procedures. All proposals passed, with annual advisory votes on compensation chosen. No questions were raised, and final results will be filed with the SEC.
Fiscal Year 2024
-
Mount Todd advanced with a completed 7,000-meter drill program, revealing new high-grade zones and supporting a feasibility study for a smaller, higher-grade project. The company holds $19 million cash, is fully permitted, and seeks a partner or transaction to unlock value.
-
Tab-cel is on track for a U.S. launch with $500M peak sales potential and significant milestone payments. The allogeneic CAR-T platform is differentiated by minimal gene editing and off-the-shelf dosing, with initial autoimmune and NHL data expected in 2025.
-
Focused on allogeneic T-cell therapies, the company is advancing off-the-shelf CAR T and dual CAR T programs, emphasizing minimal genetic modification, rapid manufacturing, and strong safety. Key clinical data in lymphoma and lupus are expected in 2024–2025, with a robust financial runway into 2027.
-
The company leverages EBV-specific T-cells for scalable allogeneic CAR-T therapies, with Tab-cel commercialized in Europe and a U.S. approval decision expected in January 2025. Pipeline assets target oncology and autoimmune diseases, supported by strong preclinical and early clinical data. Financial runway extends into 2027, with significant milestone payments anticipated.
-
The presentation highlighted a differentiated, off-the-shelf T-cell therapy platform with EU approval and a US PDUFA date in January, targeting oncology and autoimmune indications. Rapid manufacturing, strong safety, and efficacy data support expansion into lupus and dual CAR-T programs.
-
A leading allogeneic T-cell therapy platform highlighted its differentiated approach using EBV T-cells, enabling rapid, off-the-shelf treatments for cancer and autoimmune diseases. Key milestones include phase I data for ATA3219 in 2025, a PDUFA decision for tabelecleucel in January 2025, and strong financial backing through a major partnership.
-
The conference highlighted a unique allogeneic T-cell therapy platform with the only approved product in its class, ongoing U.S. regulatory review, and a differentiated CAR T program (ATA3219) entering clinical trials for lymphoma and autoimmune diseases. Commercialization plans include a major partnership and milestone payments.
-
A unique allogeneic T-cell therapy platform is advancing in oncology and autoimmune diseases, with the first approved product in Europe and a US launch expected in early 2025. Lead CAR-T programs target NHL, lupus nephritis, and SLE, with robust clinical and commercial strategies and funding secured through 2027.
-
The platform leverages donor-derived allogeneic EBV T cells for innovative immunotherapies, with ATA3219 and ATA3431 advancing in oncology and autoimmune trials. Tab-cel's EU launch is strong, with U.S. approval expected in 2025. Strategic partnerships and scalable manufacturing support broad expansion.
-
The meeting covered board introductions, voting on eight key proposals, and confirmation of a quorum. All proposals except the automatic annual increase to the equity plan were approved, with full results to be published in a Form 8-K.